Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location

Hereditary Angioedema Clinical Trials

A listing of Hereditary Angioedema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (10) clinical trials

Winthrop University Hospital Clinical Trials Center is seeking volunteers with inadequately controlled Hereditary Angioedema (HAE) for a clinical research study to test a medication already approved by the Food and Drug Administration (FDA) to investigate the safety and effectiveness of a higher dosage not approved by the FDA. Patient Inclusion ...

Phase N/A

Winthrop University Hospital Clinical Trials Center is Seeking participants that are at least 16 years of age and have been diagnosed with Acute Hereditary Angioedema. Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE ...

Phase

The purpose of this clinical research study to test how well and how safe an investigational medication works in children and adolescent with HAE. Winthrop University Hospital Clinical Trials Center is conducting this clinical research study for children and adolescents, ages 2- 15 years old who have been diagnosed with ...

Phase N/A

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

This pilot study is an open-label, non-randomized, single-arm study to evaluate the tolerability and safety of a single SC administration of ecallantide in up to approximately 10 pediatric subjects with HAE during an initial acute attack. The study is planned to enroll subjects 2 through 15 years of age who ...

Phase

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

This 2-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks. Assuming successful completion of Part 1, ...

Phase

Biomarker for Hereditary Angioedema Disease Type 1

Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Usually, this swelling is ...

Phase N/A

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly ...

Phase

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

The Firazyr® Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr® in countries where it is currently approved. The entry of patients into the Firazyr® Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr®.

Phase N/A

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

Phase